Bextra and Heart Risk: Pfizer Calls New York Times Article "Unsubstantiated"

According to a study presented at an American Heart Association meeting on November 8, 2004 and reported in the New York Times, Bextra (Pfizer's arthritis medication in the class of drugs known as COX-2 inhibitors - the same class as Celebrex and recently-recalled Vioxx) has shown an increased risk of heart attacks and strokes. Pfizer reacted quickly to the claim by calling the report "unsubstantiated and misleading". Read the details.